PE20090074A1 - DERIVADOS DE BENCIMIDAZOL COMO MODULADORES DE LOS RECEPTORES DE GLUTAMATO METABOTROPICOS (mGluR) - Google Patents

DERIVADOS DE BENCIMIDAZOL COMO MODULADORES DE LOS RECEPTORES DE GLUTAMATO METABOTROPICOS (mGluR)

Info

Publication number
PE20090074A1
PE20090074A1 PE2008000666A PE2008000666A PE20090074A1 PE 20090074 A1 PE20090074 A1 PE 20090074A1 PE 2008000666 A PE2008000666 A PE 2008000666A PE 2008000666 A PE2008000666 A PE 2008000666A PE 20090074 A1 PE20090074 A1 PE 20090074A1
Authority
PE
Peru
Prior art keywords
chloro
imidazol
pyridin
benzo
nitro
Prior art date
Application number
PE2008000666A
Other languages
English (en)
Inventor
Ralf Glatthar
David Carcache
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38654771&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090074(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20090074A1 publication Critical patent/PE20090074A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE BENCIMIDAZOL DE FORMULA (I) DONDE X1, X2, X3 Y X4 SON CADA UNO CR2 O N, EN DONDE R2 ES H, HALOGENO, NITRO, CN, FORMILO, ENTRE OTROS; R1 ES ALQUILO(C1-C6), HALOALQUILO(C1-C6), CICLOALQUILO(C3-C12), ENTRE OTROS; B ES UN COMPUESTO DE FORMULA (B1), (B2), (B3) O (B4) EN DONDE Y1, Y2, Y3 E Y4 SON CADA UNO CR3 O N; Y5 E Y6 SON CADA UNO CR3 O N, DONDE R3 ES H, HALOGENO, HIDROXILO, NITRO, CARBOXILO, ENTRE OTROS; Y7 ES O, S O N(R3a), EN DONDE R3a ES H, ALQUILO(C1-C6), HALOALQUILO(C1-C6), CICLOALQUILO(C3-C12), ENTRE OTROS; C ES UN SISTEMA DE ANILLO AROMATICO DE 5 A 12 MIEMBROS SUSTITUIDO CON Rb, EN DONDE Rb ES HALOGENO, NITRO, CN, FORMILO, AMINO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: [3-CLORO-5-(1-METIL-1H-BENZO-IMIDAZOL-2-IL)-PIRIDIN-2-IL]-(4-CLORO-FENIL)-AMINA, [3-CLORO-5-(1-ETIL-1H-BENZO-IMIDAZOL-2-IL)-PIRIDIN-2-IL]-(4-CLORO-FENIL)-AMINA, (4-CLORO-FENIL)-[3-CLORO-5-(1-PROPIL-1H-BENZO-IMIDAZOL-2-IL)-PIRIDIN-2-IL]-AMINA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LOS RECEPTORES DE GLUTAMATO METABOTROPICOS (mGluR) SIENDO UTILES EN EL TRATAMIENTO DE ISQUEMIAS CEREBRALES, ESPASMOS MUSCULARES, ENFERMEDAD DE REFLUJO GASTRO-ESOFAGICO, INCONTINENCIA URINARIA, HIPERPLASIA PROSTATICA BENIGNA
PE2008000666A 2007-04-19 2008-04-17 DERIVADOS DE BENCIMIDAZOL COMO MODULADORES DE LOS RECEPTORES DE GLUTAMATO METABOTROPICOS (mGluR) PE20090074A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07106537 2007-04-19

Publications (1)

Publication Number Publication Date
PE20090074A1 true PE20090074A1 (es) 2009-03-02

Family

ID=38654771

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000666A PE20090074A1 (es) 2007-04-19 2008-04-17 DERIVADOS DE BENCIMIDAZOL COMO MODULADORES DE LOS RECEPTORES DE GLUTAMATO METABOTROPICOS (mGluR)

Country Status (15)

Country Link
US (1) US20090105266A1 (es)
EP (1) EP2146969A1 (es)
JP (1) JP2010524892A (es)
KR (1) KR20090130141A (es)
CN (1) CN101679299A (es)
AR (1) AR068072A1 (es)
AU (1) AU2008240790A1 (es)
BR (1) BRPI0810653A2 (es)
CA (1) CA2682676A1 (es)
CL (1) CL2008001114A1 (es)
EA (1) EA200901379A1 (es)
MX (1) MX2009011208A (es)
PE (1) PE20090074A1 (es)
TW (1) TW200904425A (es)
WO (1) WO2008128968A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0606774D0 (en) * 2006-04-03 2006-05-10 Novartis Ag Organic compounds
WO2010135493A2 (en) * 2009-05-20 2010-11-25 Emory University Alzheimer's disease imaging agents
EP2390245A1 (en) * 2010-05-26 2011-11-30 Nabriva Therapeutics AG Enantiomerically pure amines
AU2012232711B2 (en) * 2011-03-18 2016-04-28 Novartis Ag Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease
JPWO2013081094A1 (ja) * 2011-11-30 2015-04-27 東レ株式会社 イミダゾ［１，２−ａ］ピリジン誘導体及びその医薬用途
EP2852586A1 (en) 2012-03-16 2015-04-01 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9233961B2 (en) 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US10939682B2 (en) 2013-07-02 2021-03-09 Syngenta Participations Ag Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
CN106029666B (zh) 2013-12-19 2018-05-18 诺华股份有限公司 作为原生动物蛋白酶体抑制剂用于治疗寄生虫疾病例如利什曼病的[1,2,4]***并[1,5-a]嘧啶衍生物
JP6689821B2 (ja) 2014-08-12 2020-04-28 シンジェンタ パーティシペーションズ アーゲー 硫黄含有置換基を有する殺有害生物的に活性な複素環式誘導体
US10308650B2 (en) 2014-12-11 2019-06-04 Syngenta Participations Ag Pesticidally active tetracyclic derivatives with sulfur containing substituents
AU2015369690B2 (en) 2014-12-23 2019-01-17 SMA Therapeutics Inc. 3,5-diaminopyrazole kinase inhibitors
CN107531704B (zh) 2015-04-24 2021-01-01 先正达参股股份有限公司 具有硫取代的五元环杂环的杀有害生物活性多环衍生物
US10125139B2 (en) 2015-04-24 2018-11-13 Syngenta Crop Protection Ag Pesticidally active polycyclic derivatives with sulfur substituted five-membered ring heterocycles
BR112018000052A2 (pt) 2015-07-01 2018-09-04 Syngenta Participations Ag derivados policíclicos ativos em termos pesticidas com substituintes contendo enxofre
WO2017001314A1 (en) 2015-07-01 2017-01-05 Syngenta Participations Ag Pesticidally active polycyclic derivatives with sulfur containing substituents
WO2017087905A1 (en) 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
BR112018010347A2 (pt) 2015-11-23 2018-12-04 Syngenta Participations Ag derivados heterocíclicos ativos em termos pesticidas com substituintes contendo enxofre e ciclopropila
CR20180592A (es) 2016-06-16 2019-03-05 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
CN114456164B (zh) 2016-10-27 2024-03-12 先正达参股股份有限公司 具有硫和羟胺取代基的杀有害生物活性杂环衍生物
WO2018091389A1 (en) 2016-11-17 2018-05-24 Syngenta Participations Ag Pesticidally active heterocyclic derivatives with sulphur containing substituents
BR112019012127A2 (pt) 2016-12-15 2019-11-05 Syngenta Participations Ag derivados heterocíclicos ativos em termos pesticidas com substituintes contendo enxofre
EP3562306A4 (en) * 2016-12-29 2020-06-24 Selenity Therapeutics (Bermuda), Ltd. METALLOENZYME INHIBITOR COMPOUNDS
KR20190129034A (ko) 2016-12-29 2019-11-19 세레니티 테라퓨틱스 (버뮤다), 리미티드 금속효소 억제제 화합물
KR102648947B1 (ko) 2017-04-26 2024-03-18 바실리어 파마슈티카 인터내셔널 리미티드 푸라자노벤즈이미다졸 및 이의 결정 형태의 제조 공정
WO2018215304A1 (en) 2017-05-22 2018-11-29 Syngenta Participations Ag Tetracyclic pyridazine sulphur containing compounds and their use as pesticides
US11399542B2 (en) 2017-07-05 2022-08-02 Syngenta Participations Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
KR20210014651A (ko) 2018-05-22 2021-02-09 니혼노야쿠가부시키가이샤 벤즈이미다졸 화합물 또는 그의 염류 및 해당 화합물을 함유하는 농원예용 살충 살진드기제 그리고 그의 사용 방법
AR115495A1 (es) 2018-06-06 2021-01-27 Syngenta Crop Protection Ag Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas
US20220185797A1 (en) * 2019-03-25 2022-06-16 The Trustees Of Columbia Universityin The City Of New York Selective foxo inhibitors for treatment of diabetes and other disorders related to impaired pancreatic function
MA55596A (fr) * 2019-04-10 2022-02-16 Cellestia Biotech Ag Inhibiteurs de la voie de signalisation notch et leur utilisation dans le traitement de cancers
AU2022286144A1 (en) * 2021-06-02 2024-01-18 Nihon Nohyaku Co., Ltd. Benzimidazole compound or salt thereof, canine filariasis control agent containing same, and method of use thereof
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ524101A (en) * 2000-08-08 2004-11-26 Ortho Mcneil Pharm Inc Neuroprotective 2-pyridinamine compositions and related methods for reducing ischemic death of cells or neuronal cell death
JP2004528304A (ja) * 2001-03-12 2004-09-16 アバニール・ファーマシューティカルズ ＩｇＥを調節し、細胞増殖を阻害するためのベンゾイミダゾール化合物
WO2004024074A2 (en) * 2002-09-13 2004-03-25 Merck & Co., Inc. Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
CA2555402A1 (en) * 2004-02-12 2005-09-01 Celine Bonnefous Bipyridyl amides as modulators of metabotropic glutamate receptor-5
CA2561718A1 (en) * 2004-04-13 2005-10-27 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators

Also Published As

Publication number Publication date
US20090105266A1 (en) 2009-04-23
AU2008240790A1 (en) 2008-10-30
WO2008128968A1 (en) 2008-10-30
BRPI0810653A2 (pt) 2014-11-04
MX2009011208A (es) 2009-10-30
CA2682676A1 (en) 2008-10-30
TW200904425A (en) 2009-02-01
JP2010524892A (ja) 2010-07-22
KR20090130141A (ko) 2009-12-17
CL2008001114A1 (es) 2008-12-19
EA200901379A1 (ru) 2010-04-30
CN101679299A (zh) 2010-03-24
EP2146969A1 (en) 2010-01-27
AR068072A1 (es) 2009-11-04

Similar Documents

Publication Publication Date Title
PE20090074A1 (es) DERIVADOS DE BENCIMIDAZOL COMO MODULADORES DE LOS RECEPTORES DE GLUTAMATO METABOTROPICOS (mGluR)
PE20130235A1 (es) Derivados de aminopirimidina como moduladores de la lrrk2
PE20141308A1 (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20141283A1 (es) Nuevos derivados biciclicos de dihidroisoquinolin-1-ona
PE20081887A1 (es) Nuevo compuesto de adenina
PE20080278A1 (es) Compuestos de benzimidazolilo
PE20130576A1 (es) Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10
UY31614A1 (es) Nuevos compuestos de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol y métodos de uso de los mismos.
PE20060526A1 (es) Compuestos triciclicos como antagonistas de mglur1
PE20141529A1 (es) Derivados de biciclo [3,2,1] octilamida y sus usos
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
CL2009000724A1 (es) Compuestos derivados de 1,2,3,4-tetrahidro-pirido[3,4-b]indol, moduladores del receptor de histamina, serotonina y dopamina; composicion farmaceutica; kit farmaceutico; y uso para tratar un trastorno cognitivo, psicotico, mediado por neurotransmisores y/o neurologico.
PA8504801A1 (es) Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas
PE20070978A1 (es) COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
CR10243A (es) "bencimidazoles 2-sustituidos como modulares de receptor de androgeno selectivos"
ECSP11011561A (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
PE20091379A1 (es) Piridinil amidas para el tratamiento de transtornos del snc y metabolicos
AR069524A1 (es) Derivados de isoxazolo - pirazina, un procedimiento para la preparacion del compuesto, medicamento en base al compuesto y uso del compuesto para preparar un medicamento
PE20070206A1 (es) Compuestos heterociclicos como inhibidores de la catecol-o-metiltransferasa
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
PE20081612A1 (es) Analogos de las pterinas
UY31436A1 (es) Nuevos compuestos tetracíclicos
PE20090622A1 (es) Nuevos derivados de bencimidazol sustituido
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal